This article was originally published in The Gray Sheet
Firms receive second request for information from the Federal Trade Commission regarding Tyco's proposed acquisition of respiratory products maker Mallinckrodt for about $4.2 bil., announced June 28 (1"The Gray Sheet" July 3, 2000, p. 7). According to Tyco, the request relates specifically to the firms' respective sales of endotracheal tubes, and revenues from that product line amount to "less than $20 mil." The request raises the possibility that the FTC may require Tyco to divest the business before approving the overall deal. The firms still hope to close the deal by September
You may also be interested in...
Tyco International's decision to account for its $4.2 bil. stock acquisition of Mallinckrodt as a purchase rather than a pooling-of-interests transaction, gives the company the flexibility to divest Mallinckrodt's imaging drugs and bulk pharmaceuticals businesses and concentrate on the fast-growing respiratory products division.
Verona Pharma’s candidate COPD therapy ensifentrine has a first-in-class dual mechanism of action and is to be explored as an add-on to LAMA and LABA therapy in two Phase III clinical studies.
No device-related warning letters were released by the US FDA the week of 2 June.